Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 10, 2019 9:30 AM - Nov 12, 2019 5:40 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

16th DIA Japan Annual Meeting 2019

Delivering Rational Medicine for All People in the Globe

[S15] Lessens from Experiences Using MidNet for PV

Session Chair(s)

Yoshiaki  Uyama, PhD, RPh

Yoshiaki Uyama, PhD, RPh

Associate Executive Director

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

So far, there have been three cases of the use of MID-NET, a government-owned database which has become available since April 2018. These three companies are invited to talk about their experience of using MID-MET from various perspectives such as data accumulation, data analysis, information delivery and discuss issues in using the database. In the panel, a representative of MID-NET devision of PMDA will also invited and the future perspective of the utilization of MID-NET for pharmacovigilance as well as the issues to overcome for a full utilization of the database.


Katsuhiko  Ichimaru

Overview of Utilization of MID-NET

Katsuhiko Ichimaru

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Review Director, Office of New Drug IV

Kei  Sagawa

Practice of MID-NET Use in Post-Marketing Database Study

Kei Sagawa

Daiichi Sankyo Co., Ltd., Japan

Pharmacovigilance, Safety and Risk Management Department

Makoto  Miyazaki, MSc

Utilization of MID-NET from Pharmacovigilance Perspective

Makoto Miyazaki, MSc

Japan Pharmaceutical Manufacturers Association (JPMA) / MSD K.K. , Japan

Shintaro  Hiro, PhD

Recommendations on Feasibility Assessment to Leverage MID-NET

Shintaro Hiro, PhD

Pfizer R&D Japan, Japan

Manager, Data Science & Analytics Japan Lead, Clinical Statistics

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.